Cutaneous Effects of Sirolimus in Renal Transplant Recipients

March 2006 | Volume 5 | Issue 3 | Original Article | 273 | Copyright © March 2006

Lindsey Warino BS, James Libecco MD

Abstract
Cancer is a major cause of death in immunosuppressed transplant patients. Therefore, sirolimus is frequently used in these patients for its immunosuppressive and antineoplastic properties. However, a variety of cutaneous side effects have resulted from sirolimus therapy. Consequently, dermatologists must be aware of such adverse events and understand the risks and benefits of discontinuing therapy.